On November 5, 2019 Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, reported that it will report its third quarter 2019 financial results on Tuesday, November 12, 2019 (Press release, Gossamer Bio, NOV 5, 2019, View Source [SID1234550359]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In connection with the earnings release, Gossamer’s management team will host a live conference call and webcast at 4:30 p.m. ET on Tuesday, November 12, 2019 to discuss the Company’s financial results and provide a corporate update.
The live audio webcast may be accessed through the "Events and Presentations" page in the "Investors" section of the Company’s website at View Source Alternatively, the conference call may be accessed through the following:
Conference ID: 1981058
Domestic Dial-in Number: (866) 221-1654
International Dial-in Number: (470) 495-9466
Live Webcast: View Source
A replay of the audio webcast will be available for 30 days on the Investors section of the Company’s website, www.gossamerbio.com.